ENTA ENANTA PHARMACEUTICALS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1177648 · Fiscal year ends 09/30
Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY0.7%
TTM net income YoY31.3%
TTM EPS YoY44.0%
Revenue 3-yr CAGR-6.8%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-90.0%
Net margin-96.9%
FCF margin-56.6%
EBITDA margin-82.5%
Returns
ROE-70.1%
ROA-21.2%
ROIC (approx.)-90.9%
Asset turnover0.22x
Leverage & solvency
Liabilities / assets66.0%
Debt / equity0.00x
Current ratio3.76x
Interest coverage-4.55x
Cash quality & payout
Operating cash flow / net income0.56x
Accruals ratio-9.3%
Payout ratio—
Capex / revenue2.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-09-30 | FY20242024-09-30 | FY20232023-09-30 | FY20222022-09-30 | FY20212021-09-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $65.32M | $67.64M | $79.20M | $86.16M | $97.07M |
| R&D expense | $106.74M | $131.48M | $163.52M | $164.52M | $174.11M |
| SG&A expense | $43.93M | $57.85M | $52.89M | $45.48M | $32.54M |
| Operating income | -$85.35M | -$121.69M | -$137.21M | -$123.84M | -$109.57M |
| Interest expense | $7.68M | $10.94M | $5.15M | $0 | $0 |
| Pretax income | -$83.55M | -$117.79M | -$131.00M | -$122.19M | -$107.58M |
| Income tax | -$1.66M | -$1.74M | $2.82M | -$433,000 | -$28.58M |
| Net income | -$81.89M | -$116.05M | -$133.82M | -$121.75M | -$79.00M |
| EBITDA | -$80.76M | -$119.36M | -$134.84M | -$120.87M | -$106.24M |
| EPS (basic) | -3.84 | -5.48 | -6.38 | -5.91 | -3.92 |
| EPS (diluted) | -3.84 | -5.48 | -6.38 | -5.91 | -3.92 |
| Weighted avg. shares (diluted) | 21,336 | 21,157 | 20,969 | 20,603 | 20,171 |
| Balance sheet | |||||
| Cash & equivalents | $32.30M | $37.23M | $85.39M | $43.99M | $57.21M |
| Short-term investments | $156.57M | $210.95M | $284.52M | $205.24M | $186.80M |
| Receivables | $6.88M | $6.65M | $8.61M | $20.32M | $23.58M |
| Current assets | $204.34M | $299.85M | $422.79M | $311.71M | $319.02M |
| PP&E, net | $35.40M | $32.69M | $11.92M | $6.17M | $5.94M |
| Total assets | $280.73M | $376.65M | $462.27M | $375.41M | $438.79M |
| Current liabilities | $48.55M | $57.53M | $62.79M | $29.83M | $36.17M |
| Total liabilities | $216.01M | $247.84M | $245.54M | $54.08M | $39.36M |
| Shareholders' equity | $64.72M | $128.81M | $216.74M | $321.33M | $399.43M |
| Shares outstanding | 21.39M | 21.39M | 21.06M | 20.79M | 20.24M |
| Cash flow statement | |||||
| Operating cash flow | -$19.27M | -$78.76M | -$103.15M | -$84.78M | -$70.00M |
| Capital expenditure | $12.90M | $17.95M | $9.06M | $2.12M | $750,000 |
| Free cash flow | -$32.17M | -$96.71M | -$112.21M | -$86.91M | -$70.75M |
| Investing cash flow | $40.35M | $58.23M | -$53.58M | $54.90M | $36.99M |
| Financing cash flow | -$26.62M | -$27.63M | $198.13M | $20.03M | $3.08M |
| Depreciation & amortization | $4.59M | $2.34M | $2.37M | $2.97M | $3.33M |
| Stock-based compensation | $18.57M | $26.80M | $28.22M | $26.97M | $20.99M |
Free plan shows the latest 5 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.